Yıl: 2021 Cilt: 69 Sayı: 1 Sayfa Aralığı: 74 - 83 Metin Dili: İngilizce DOI: 10.5578/tt.20219909

The effect of tocilizumab on severe COVID-19 infection: Review of current evidence

Öz:
The COVID-19 outbreak that spread in December 2019 has caused the death of millions of people in a short time. Many studies published recently have shown that many cytokines (interleukin (IL) IL-1, IL-2, IL-6, TNF and IFN-) are significantly increased in COVID-19 patients with pneumonia, and especially IL-6 in combination with other cytokines has shown to be the main cause of the cytokine storm. Since IL-6 level is associated with clinical worsening in COVID-19 patients, anti-IL-6 therapy is seen as a promising treatment. Tocilizumab, a widely used IL-6 antagonist, was approved by the FDA in 2017 for Cytokine Storm Syndrome (CSS). Its addition to the treatment in COVID19 patients with increased blood IL-6 levels and oxygen saturation <92% has been recommended due to bilateral widespread pulmonary infiltration. We summarized the studies on tocilizumab and COVID-19 disease published in the literature. In the light of current information, data on the mechanism of the action of tocilizumab, which is still widely used in COVID-19 patients, appropriate patient selection, effectiveness in treatment and side effects are presented.
Anahtar Kelime:

Konular:
Fen > Tıp > Kulak, Burun, Boğaz
Fen > Tıp > Solunum Sistemi

Ağır COVID-19 enfeksiyonunda tosilizumab'ın etkinliği: Güncel çalışmaların derlemesi

Öz:
Aralık 2019’da başlayan COVID-19 salgını, kısa sürede milyonlarca insanın ölümüne yol açmıştır. Yakın zamanda yayınlanan çalışmalar, pnömoni ile seyreden COVID-19 hastalarında birçok sitokinin (IL-1, IL-2, IL-6, TNF ve IFN-γ) önemli ölçüde arttığını ve özellikle Interlökin 6 (IL-6)’nın diğer sitokinlerle birlikte sitokin fırtınasının ana nedeni olduğunu göstermiştir. IL-6 düzeyi, COVID-19 hastalarında klinik kötüleşme ile ilişki bulunduğundan dolayı, anti-IL 6 tedavisi umut vaad eden tedavi olarak görülmektedir. Yaygın kullanılan IL-6 antagonisti olan Tosilizumab’ın 2017 yılında FDA tarafından Sitokin Fırtınası Sendromu için kullanımı onaylanmıştır. Kanda IL-6 düzeyi yükselmiş, akciğerde bilateral yaygın infiltrasyonu nedeniyle oksijen satürasyonu <%92 olan COVID-19 hastalarında tedaviye eklenmesi önerilmektedir. Bu çalışmada, 20 Ekim 2020’ye kadar literatürde yayınlanan Tosilizumab ve COVID-19 ile ilgili araştırmalar, meta-analizler ve randomize çalışmalar tarandı. Güncel bilgiler ışığında halen yaygın kullanımda olan Tosilizumab’ın COVID-19 hastalarında etki mekanizması, uygun hasta seçimi, tedavideki etkinliği ve yan etkileri hakkında veriler sunuldu.
Anahtar Kelime:

Konular:
Fen > Tıp > Kulak, Burun, Boğaz
Fen > Tıp > Solunum Sistemi
Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. World Health Organization (WHO). Coronavirus Disease (COVID-19) Dashboard. Accessed date: 15 Nov 2020. Available from: https://covid19.who.int
  • 2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054-62.
  • 3. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46: 846-8.
  • 4. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. Rev Med Virol 2020; 30(6): 1-9.
  • 5. Cortegiani A, Ippolito M, Ingoglia G, Einav S. Chloroquine for COVID-19: rationale, facts, hopes. Crit Care 2020; 8; 24(1): 210.
  • 6. Tufan A, Avanoğlu Güler A, Matucci-Cerinic M. COVID19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci 2020; 21; 50(SI-1): 620-32.
  • 7. The U.S. Food and Drug Administration. Information for ACTEMRA. Accessed date: 15 Nov 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2017/125276s114lbl.pdf.
  • 8. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG, et al. Into the eye of the cytokine storm. Microbiol Mol Biol Rev 2012; 76(1): 16-32.
  • 9. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395(10223): 497-506.
  • 10. Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMed 2020; 55: 102763.
  • 11. Zhai H, Liu Y, Wang Y, Li X, Li T. The pathogen distribution and its influence on inflammatory factors in old patients with heart failure complicated with pulmonary infection. Tianjin Med J 2018; 46(9): 952-5.
  • 12. Yonggang Z, Binqing F, Xiaohu Z, Dongsheng W, Changcheng Z, Yingjie Q, et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Nat Sci Rev 2020; 7(6): 998- 1002.
  • 13. Ferrara JL, Abhyankar S, Gilliland DG. Cytokine storm of graftversus-host disease: a critical efector role for interleukin-1. Transplant Proc 1993; 25(1 Pt 2): 1216-17.
  • 14. De Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, et al. Fatal outcome of human infuenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12(10): 1203-7.
  • 15. Teachey DT, Lacey SF, Shaw PA, Melenhorst JJ, Maude SL, Frey N, et al. Identifcation of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016; 6(6): 664-79.
  • 16. Tanaka T, Narazaki M, Kishimoto T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 2016; 8(8): 959-70.
  • 17. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in infammatory diseases and cancer. Nat Rev Immunol 2018; 18(12): 773-89.
  • 18. Braun GS, Nagayama Y, Maruta Y, Heymann F, van Roeyen CR, Klinkhammer BM, et al. IL-6 trans-signaling drives murine crescentic GN. Am Soc Nephrol 2016; 27(1): 132-42.
  • 19. Rose-John S. The soluble Interleukin 6 receptor: advanced therapeutic options in inflammation. Clin Pharmacol Ther 2017; 102(4): 591-8.
  • 20. Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis 2020; 95: 332-9.
  • 21. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020: 25; 58(7): 1021-8.
  • 22. Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med 2017; 45: 124-31.
  • 23. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378(5): 439-48.
  • 24. Wei P-F. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7). Chin Med J 2020; 133: 1087-95.
  • 25. Gul MH, Htun ZM, Shaukat N, Imran M, Khan A. Potential specific therapies in COVID-19. Ther Adv Respir Dis 2020; 14: 1753466620926853.
  • 26. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA 2020; 19; 117(20): 10970-5.
  • 27. Sarhan RM, Madney YM, Abou Warda AE, Boshra MS. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab. Int J Clin Pract 2021; 6: 14079.
  • 28. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med 2020; l76: 31-35.
  • 29. Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020; l2; 8: 474-84.
  • 30. Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single-center study of 100 patients in Brescia, Italy. Autoimmun Rev 2020; 19: 102568.
  • 31. Moreno Garcia E, Rico Caballero V, Albiach L, Aguero D, Ambrosioni J, et al. Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. medRxiv 2020; 20113738.
  • 32. Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, et al. Tocilizumab for patients with COVID19 pneumonia. The single-arm TOCIVID-19 prospective trial. J Transl Med 2020; 18(1): 405.
  • 33. Somers EC, Eschenauer GA, Troost JP, Golob JL, Gandhi TN, et al. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. Clin Infect Dis 2020; ciaa954.
  • 34. Martínez-Sanz J, Muriel A, Ron R, Herrera S, Pérez-Molina JA, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: a multicentre cohort study. Clin Microbiol Infect 2020; 27(2): 238-43.
  • 35. Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes. Chest 2020; 158(4): 1397-408.
  • 36. Rossi B, Nguyen LS, Zimmermann P, Boucenna F, Dubret L, Baucher L, et al. Effect of tocilizumab in hospitalized patients with severe COVID-19 pneumonia: a case-control cohort study. Pharmaceuticals (Basel) 2020; 17; 13(10): 317.
  • 37. Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax medRxiv 2020; 20076612.
  • 38. Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med 2021; 181(1): 41-51.
  • 39. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med 2021; 384(1): 20-30.
  • 40. Rajendram P, Sacha GL, Mehkri O, Wang X, Han X, Vachharajani V, Duggal A. Tocilizumab in coronavirus disease 2019-related critical illness: a propensity matched analysis. Crit Care Explor 2021; 3(1): 0327.
  • 41. Kow CS, Hasan SS. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2021; 2: 1-6.
  • 42. Campochiaro C, Della-Torre E, Cavalli G, De Luca G, Ripa M, Boffini N, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-center retrospective cohort study. Eur J Intern Med 2020; 76: 43-9.
  • 43. Colaneri M, Bogliolo L, Valsecchi P, Sacchi P, Zuccaro V, Brandolino F, et al. Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms 2020; 8: 695.
  • 44. Ip A, Berry DA, Hansen E, Goy AH, Pecora AL, Sinclaire BA, et al. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-an observational study. PLoS One 2020; 13; 15(8): 0237693.
  • 45. Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med 2020; 383: 2333-44.
  • 46. Stone JH, Horick NK, Healy BC. Tocilizumab in Covid-19 Reply. N Engl J Med 2021; 384(1): 87.
  • 47. Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, et al. Eficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 2018; 77(3): 348-54.
  • 48. Samson M, Devilliers H, Ly KH, Maurier F, Bienvenu B, Terrier B, et al. Tocilizumab as an addon therapy to glucocorticoids during the frst 3 months of treatment of giant cell arteritis: a prospective study. Eur J Intern Med 2018; 57: 96-104.
  • 49. Helleberg M, Steensen M, Arendrup MC. Invasive aspergillosis in patients with severe COVID-19 pneumonia. Clin Microbiol Infect 2021; 27(1): 147-8.
  • 50. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 15; 112(10): 3959- 64.
  • 51. Morena V, Milazzo L, Oreni L, Bestetti G, Fossali T, Bassoli C, et al. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Eur J Intern Med 2020; 76: 36-42.
  • 52. Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severities: a multicenter study of clinical features. Am J Respir Crit Care Med 2020; 201(11): 1380-8.
  • 53. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med 2020; 11; 382(24): 2372-4.
  • 54. Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacother 2020; 40(5): 416-37.
APA YAKAR H, PAZARLI A, KÖSEOĞLU H, KANBAY A (2021). The effect of tocilizumab on severe COVID-19 infection: Review of current evidence . Tüberküloz ve Toraks, 69(1), 74 - 83. 10.5578/tt.20219909
Chicago YAKAR Halil İbrahim,PAZARLI Ahmet Cemal,KÖSEOĞLU Handan İnönü,KANBAY Asiye The effect of tocilizumab on severe COVID-19 infection: Review of current evidence . Tüberküloz ve Toraks 69, no.1 (2021): 74 - 83. 10.5578/tt.20219909
MLA YAKAR Halil İbrahim,PAZARLI Ahmet Cemal,KÖSEOĞLU Handan İnönü,KANBAY Asiye The effect of tocilizumab on severe COVID-19 infection: Review of current evidence . Tüberküloz ve Toraks, vol.69, no.1, 2021, ss.74 - 83. 10.5578/tt.20219909
AMA YAKAR H,PAZARLI A,KÖSEOĞLU H,KANBAY A The effect of tocilizumab on severe COVID-19 infection: Review of current evidence . Tüberküloz ve Toraks. 2021; 69(1): 74 - 83. 10.5578/tt.20219909
Vancouver YAKAR H,PAZARLI A,KÖSEOĞLU H,KANBAY A The effect of tocilizumab on severe COVID-19 infection: Review of current evidence . Tüberküloz ve Toraks. 2021; 69(1): 74 - 83. 10.5578/tt.20219909
IEEE YAKAR H,PAZARLI A,KÖSEOĞLU H,KANBAY A "The effect of tocilizumab on severe COVID-19 infection: Review of current evidence ." Tüberküloz ve Toraks, 69, ss.74 - 83, 2021. 10.5578/tt.20219909